Financial reports
10-K
2023 FY
Annual report
22 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
24 Feb 22
Current reports
8-K
Departure of Directors or Certain Officers
22 Mar 24
8-K
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
22 Feb 24
8-K
Departure of Directors or Certain Officers
1 Feb 24
8-K
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
8 Jan 24
8-K
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
21 Dec 23
8-K
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
19 Dec 23
8-K
Other Events
15 Nov 23
8-K
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
6 Nov 23
8-K
Departure of Directors or Certain Officers
3 Nov 23
8-K
Regulation FD Disclosure
7 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
23 Feb 24
424B5
Prospectus supplement for primary offering
21 Dec 23
S-8
Registration of securities for employees
10 Aug 23
424B5
Prospectus supplement for primary offering
23 May 23
424B5
Prospectus supplement for primary offering
22 May 23
S-3ASR
Automatic shelf registration
22 May 23
S-8
Registration of securities for employees
2 Mar 23
S-8
Registration of securities for employees
28 Feb 22
S-8
Registration of securities for employees
1 Mar 21
424B7
Prospectus with selling stockholder info
8 Oct 20
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
8 Jun 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 19
Other
CT ORDER
Confidential treatment order
8 Feb 22
EFFECT
Notice of effectiveness
23 May 19
CORRESP
Correspondence with SEC
20 May 19
CORRESP
Correspondence with SEC
20 May 19
UPLOAD
Letter from SEC
15 May 19
CT ORDER
Confidential treatment order
4 Oct 18
EFFECT
Notice of effectiveness
4 Oct 18
CERT
Certification of approval for exchange listing
2 Oct 18
CORRESP
Correspondence with SEC
1 Oct 18
CORRESP
Correspondence with SEC
1 Oct 18